Lionel Adès, MD, PhD, spoke with Blood Cancers Today about the session he presented at the 2022 SOHO Annual Meeting, highlighting three different kinds of targeted therapy that have been developed for MDS.
Lionel Adès, MD, PhD, Gives an Update on Targeted Therapies for MDS
By Kerri Fitzgerald - Last Updated: November 15, 2022Post Tags:MDS at SOHO 2022
Related Posts
This life-threatening pediatric disease can cause sideroblastic anemia, metabolic crisis, and bone marrow failure.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
ELEMENT-MDS trial tests luspatercept vs epoetin alfa for anemia in ESA-naive, lower-risk MDS without transfusion need.
Our expert roundtable reacts to data presented at ASCO 2025 on real-world use of the agent in this setting.
Experts discuss what data do clinicians need in order to optimize their first-line use of this agent for low-risk MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.